​

C4 Therapeutics (CCCC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CCCC Stock Forecast

C4 Therapeutics (CCCC) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 990.91% increase from the last price of $1.10.

- $3 $6 $9 $12 $15 High: $12 Avg: $12 Low: $12 Last Closed Price: $1.1

CCCC Stock Rating

C4 Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 2 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 2 8 Strong Sell Sell Hold Buy Strong Buy

CCCC Price Target Upside V Benchmarks

TypeNameUpside
StockC4 Therapeutics990.91%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$16.00
Last Closing Price$1.10$1.10$1.10
Upside/Downside--1354.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25154--10
Mar, 25-54--9
Feb, 25153--9
Jan, 25153--9
Dec, 24154--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 19, 2024Derek ArchilaWells Fargo$12.00$4.31178.42%990.91%
Sep 19, 2024Etzer DaroutBMO Capital$20.00$6.87191.12%1718.18%
Jan 03, 2023Wells Fargo$9.00$6.3142.63%718.18%
Apr 28, 2022Credit Suisse$10.00$8.8512.99%809.09%
Apr 11, 2022Chi FongBank of America Securities$15.00$8.0187.27%1263.64%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 19, 2024Wells FargoEqual-WeightOverweightupgrade
Sep 19, 2024BMO CapitalOutperformOutperformhold
Dec 13, 2023Piper SandlerBuyupgrade
Feb 24, 2023Credit SuisseUnderperformNeutralupgrade
Jan 03, 2023Wells FargoEqual-WeightEqual-Weighthold
Apr 28, 2022Credit SuisseUnderperforminitialise

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-1.54$-1.87$-2.59$-2.67-
Avg Forecast$-7.94$-2.05$-2.59$-2.60$-1.49
High Forecast$-7.94$-2.05$-2.59$-2.33$-1.41
Low Forecast$-7.94$-2.05$-2.59$-2.86$-1.58
Surprise %-80.60%-8.78%-2.69%-

Revenue Forecast

$15M $22M $29M $36M $43M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$33.20M$45.78M$31.10M$20.76M-
Avg Forecast$32.92M$33.08M$39.80M$21.45M$35.79M
High Forecast$32.92M$33.08M$39.80M$28.59M$40.79M
Low Forecast$32.92M$33.08M$39.80M$17.13M$30.29M
Surprise %0.85%38.40%-21.86%-3.25%-

Net Income Forecast

$-400M $-330M $-260M $-190M $-120M $-50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-66.33M$-86.04M$-126.50M$-132.49M-
Avg Forecast$-394.27M$-100.64M$-117.73M$-132.49M$-74.23M
High Forecast$-394.27M$-80.51M$-94.18M$-105.99M$-70.10M
Low Forecast$-394.27M$-120.76M$-141.28M$-158.99M$-78.37M
Surprise %-83.18%-14.51%7.45%--

CCCC Forecast FAQ

Is C4 Therapeutics stock a buy?

C4 Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that C4 Therapeutics is a favorable investment for most analysts.

What is C4 Therapeutics's price target?

C4 Therapeutics's price target, set by 10 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 990.91% change from the previous closing price of $1.1.

How does C4 Therapeutics stock forecast compare to its benchmarks?

C4 Therapeutics's stock forecast shows a 990.91% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for C4 Therapeutics over the past three months?

  • April 2025: 10.00% Strong Buy, 50.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 55.56% Buy, 44.44% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is C4 Therapeutics’s EPS forecast?

C4 Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.49, marking a -44.19% decrease from the reported $-2.67 in 2023..

What is C4 Therapeutics’s revenue forecast?

C4 Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $35.79M, reflecting a 72.43% increase from the reported $20.76M in 2023.

What is C4 Therapeutics’s net income forecast?

C4 Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-74.235M, representing a -43.97% decrease from the reported $-132M in 2023.